Targetable drug carriers: present status and a future perspective
- 16 September 1996
- journal article
- editorial
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 21 (2) , 77-80
- https://doi.org/10.1016/s0169-409x(96)00439-5
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Thermo-responsive polymer nanoparticles with a core-shell micelle structure as site-specific drug carriersJournal of Controlled Release, 1997
- Macromolecular Carrier Systems for Targeted Drug Delivery: Pharmacokinetic Considerations on BiodistributionPharmaceutical Research, 1996
- 929 Clinical phase I trial of PK1 (HPMA co-polymer doxorubicin)European Journal Of Cancer, 1995
- Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.Journal of Clinical Oncology, 1995
- Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanomaBritish Journal of Cancer, 1994
- Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly (ethylene oxide-aspartate) block copolymer-adriamycin conjugatesJournal of Controlled Release, 1994
- Targeted Chemotherapy for Unresectable Primary and Metastatic Liver CancerActa Oncologica, 1994
- Cure of Xenografted Human Carcinomas by BR96-Doxorubicin ImmunoconjugatesScience, 1993
- Block copolymer micelles as vehicles for drug deliveryJournal of Controlled Release, 1993
- Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivoBioconjugate Chemistry, 1992